Skip to main content

Pediatric Rheum

COVID Test Antibody

Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

MedPage Today
Jan 18, 2022

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Read Article
JIA,knee,synovitis

What Can JIA Patients Expect 18 Years In?

MedPage Today
Jan 12, 2022

Follow-up in a Scandinavian cohort of juvenile idiopathic arthritis (JIA) patients that began in 1997-2000 revealed a number of surprises, a new study indicated.



More than two-thirds of patients were using no drug therapies at year 18, even though only about half were in remission and

Read Article
Biomarker study of 21 systemic juvenile idiopathic arthritis (sJIA) shows you can differentiate between active & inactive disease. From 69 biomarkers, these were predictive: IL-6, MMP1, S100A12 (p < 0.0001), HMGB1; but IL-18 elevated in both groups! https://t.co/m2yXTITzwY

Dr. John Cush @RheumNow( View Tweet )

Jan 12, 2022
IV,arm,intravenous,infusion

BEAT LUPUS - Belimumab after Rituximab in SLE

Jan 11, 2022

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article
ICYMI: Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. Read more : https://t.co/OAPdLCxHgy https://t.co/0RnYKeg891
Dr. John Cush @RheumNow( View Tweet )
Jan 09, 2022
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
covid coronavirus virus

New Onset Rheumatic Disorders with COVID-19 Infection

Jan 05, 2022

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.



Infection can be an infrequent trigger to immune 

Read Article
COVID,teen,young,man,mask

Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children

Jan 05, 2022

Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. A review of proposed management guidelines is compiled in this report, suggesting a unified approach to therapeutic management of MIS-C.

Read Article
Does COVID Vax reduce adolescent MIS-C risk? In France 77% of teens recv COVID Vaccine by 10/2021. From Sept-Oct 2021,107 MIS-C kids were hospitalized in France; 31% were eligible but not vaccinated. MIS-C risk dropped 91% (0.09) after 1st first vax dose https://t.co/mF0L2VnEoi https://t.co/R33n1FCN3X
Dr. John Cush @RheumNow( View Tweet )
Jan 04, 2022
Best of 2021: A serious shortage of pediatric rheumatologists in the USA, where we need at least 1 ped rheum per 400,000 population. @RWCSmtg https://t.co/hUroLwclxz https://t.co/QHHNH99wJ0
Dr. John Cush @RheumNow( View Tweet )
Dec 31, 2021
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

Dec 31, 2021

It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen

Read Article
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
fever2.jpg

When to Stop Biologics in Systemic JIA?

Dec 13, 2021

Systemic onset juvenile idiopathic arthritis (sJIA) is a dramatic onset inflammatory condition marked by spiking fevers, intermittent rash, polyarthritis and a host of other hyperinflammatory manifestations. The condition may be well controlled in many through the use of high dose

Read Article
Watch Now: Can We Stop Medication in Systemic JIA?https://t.co/yRIb70YVME https://t.co/EJ2PmC6xKY
Dr. John Cush @RheumNow( View Tweet )
Dec 03, 2021
Pediatric Psoriatic Arthritis: Dr. Eric Ruderman ( @JointMD) discusses abstracts #1424 presented at the ACR21 annual meeting.https://t.co/aRCPAlBGev https://t.co/jsa261ZuYx
Dr. John Cush @RheumNow( View Tweet )
Dec 01, 2021
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
Sign

Emapalumab for the treatment of macrophage activation syndrome

Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly occurring in people with systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (

Read Article
#ACR21 [Dr Pooni] #Telemedicine #Pediatrics providers felt PE was worsened BUT msk exam was the MOST reliable. @endocrine_witch @millennialpediahttps://t.co/3FGCyBIxB2 https://t.co/fgwdk0WXKm
LiSa ◡̈︎ @rheumarhyme( View Tweet )
Nov 09, 2021
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Nov 09, 2021

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
Handy overview of Jak/STAT pathways in rheumatic diseases and available inhibitors (Dr. Joost Swart). Happening now in the Pediatrics Hub (New Therapies & Biologic Safety in Pediatric Rheumatology​). #ACR21 #pedsrheum https://t.co/i4bYr4GKOP
Katie Poholek @kpoho( View Tweet )
Nov 09, 2021
#ACR21 #pedsrheum I say it counts! I mean, at the end of the day, these are all just pictures of food on the internet, right? #ACRBakeAnythingChallenge https://t.co/bVQuealWWX

Dr. Laura Lewandowski @LauraLewMad11( View Tweet )

Nov 09, 2021
New dimensions in cellular immunology. Great session, some which I understood. Kids with #JIA have more cytolytic pathway missense - some leads to macrophage activation syndrome #MAS Low NK cells in Juvenile Dermatomyositis. 9T112 #ACR21 @RheumNow https://t.co/5lUkqr65UM
Nov 09, 2021
ACR Best

ACR21 Best Abstracts We Saw - Day 3 (Monday)

Nov 08, 2021

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

Read Article
Can you stop monitoring eyes in + ANA and/or pauciarticular pt who becomes an adult if no uveitis ever, in last 5 yrs, etc. When can we stop looking? #AVR21 @RheumNow https://t.co/1Ml1BuJD7Y
Nov 08, 2021
#ACR21 #pedsrheum Risk factors for poor outcomes: delay to diagnosis, poor access to therapy, poor access to care https://t.co/SlFyav5KV6
Dr. Laura Lewandowski @LauraLewMad11( View Tweet )
Nov 08, 2021
×